InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,277.51
(
0.80%
)
US TECH 100
18,064.80
(
0.02%
)
Dow Jones
38,686.32
(
1.51%
)
Brent Oil
81.30
(
0.00%
)
Bitcoin
67,625.79
(
0.21%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 830
Posts 119741
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: nivasvs post# 11952

Monday, 06/23/2008 8:19:57 AM

Monday, June 23, 2008 8:19:57 AM

Post# of 19309
The rationale for the deal is that Ovation has an established hospital salesforce for acute-care drugs in general and hematology in particular. These are the marketed products listed on the company’s website:

http://www.ovationpharma.com/products.php

HOSPITAL
Chemet®
Cogentin®
Indocin® I.V.
Intravenous Sodium Diuril®
NeoProfen®

HEMATOLOGY/ONCOLOGY
Cosmegen® for Injection
Elspar®
Mustargen®
Panhematin®

Although the fit between the companies looks good, the scant $5M in deal payments that GTC expects in 2008 is disappointing, IMO.



Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up